Vimarsana
Biggest News Aggregation in the World

Evaluator Blinded Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Evaluator Blinded Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Evaluator Blinded Study Today - Breaking & Trending Today

Neuraptive Therapeutics Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX001 for the Adjunct Treatment of Transected Peripheral Nerves - Vimarsana News

Neuraptive Therapeutics Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX001 for the Adjunct Treatment of Transected Peripheral Nerves

Published: January 9, 2024

Neuraptive Therapeutics Inc. a leader in nerve repair and regeneration is pleased to announce a significant milestone in transforming the treatment paradigm for peripheral nerve injuries.

Source: businesswireindia.com
Related Topics:
United StatesEvan TzanisRobert RadieNeuraptive Therapeutics IncChief Operating OfficerNeuraptive TherapeuticsBusiness WireEvaluator Blinded StudyTreatment Emergent Adverse EventsSerious Adverse EventsMichigan Hand QuestionnaireNumeric Pain Rating ScaleSemmes Weinstein Monofilament TestPatient Global ImpressionWeek ResultsTotal ScoreSecondary EndpointsEdge MechanismLeading ExpertsClinical TrialsMedia ContactNeuraptive Therapeutics Inc The Neurofuse Study Ntx001 Transected Peripheral Nerves Evan Tzanis Robert Radie Pegfusion Clinical Trials
Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves - Vimarsana News

Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

Published: January 8, 2024

The NEUROFUSE Study is an ongoing 48-week Multicenter, Randomized, evaluator-blinded, Phase 2a study in upper extremity nerve transections comparing NTX-001…

Source: financialpost.com
Related Topics:
United StatesNeuraptive Therapeutics IncEvaluator Blinded StudyTreatment Emergent Adverse EventsSerious Adverse EventsMichigan Hand QuestionnaireNumeric Pain Rating ScaleSemmes Weinstein Monofilament TestPatient Global ImpressionWeek ResultsTotal ScoreSecondary Endpoints